OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
105
Results
Show all
Save search
Copy query
Show results for
Unknown
(105)
Publication Date
Release Date
2020
(23)
2024
(20)
2025
(15)
2023
(13)
2022
(11)
2021
(8)
2016
(3)
2015
(3)
2008
(3)
2026
(2)
2018
(1)
2017
(1)
2013
(1)
2012
(1)
Previous
page
1 / 11
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
11
Next
page
Sort
by:
Relevance
Page size
10
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Not available
S-EPMC10101777
|
biostudies-literature
Cite
Real-world clinical evidence of lazertinib use in acquired
EGFR
T790M mutated non-small cell lung cancer.
Not available
S-EPMC10579823
|
biostudies-literature
Cite
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study.
Not available
S-EPMC10774959
|
biostudies-literature
Cite
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.
Not available
S-EPMC7577810
|
biostudies-literature
Cite
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
Not available
S-EPMC4394089
|
biostudies-literature
Cite
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC).
Not available
S-EPMC10775014
|
biostudies-literature
Cite
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Not available
S-EPMC7653133
|
biostudies-literature
Cite
Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors.
Not available
S-EPMC7947405
|
biostudies-literature
Cite
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study.
Not available
S-EPMC9359724
|
biostudies-literature
Cite
Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study.
Not available
S-EPMC12539119
|
biostudies-literature
Cite
Previous
page
1 / 11
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
11
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets